long intergenic non-protein coding RNA 1239Genealiases: []
Q-omics provides the consensus-scored LINC01239 profile across patient tissues and cancer cell-line models. LINC01239 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC01239 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC01239 RNA expression shows 12,166 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where LINC01239 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01239 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01239 survival associations across molecular data types. LINC01239 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01239 RNA expression–survival associations across cancer types. High LINC01239 expression shows unfavorable associations in UCEC, STAD, LUSC and KICH, but favorable associations in MESO and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC01239 RNA expression.
This table summarizes LINC01239 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01239. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01239 shows lower tumor expression in BRCA, COAD, LUSC and READ and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher LINC01239 RNA expression in tumor versus normal tissue (log2 FC = +0.230, t-test p < 0.001).
This table shows molecular features associated with LINC01239 in patient tissues and cancer cell lines. In patient samples, LINC01239 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
